Biological vs conventional combination treatment and work loss in early rheumatoid arthritis: A randomized trial

JAMA Internal Medicine

Volumn 173, Issue 15, 2013, Pages 1407-1414

  Eriksson, Jonas K ^a   Neovius, Martin ^a   Bratt, Johan ^a   Petersson, Ingemar F ^b   Van Vollenhoven, Ronald F ^a   Geborek, Pierre ^b   Ernestam, Sofia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SOCIAL INSURANCE; WORK DISABILITY;

EID: 84882282795     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.7801     Document Type: Article

References (32)

1. Helmick CG, Felson DT, Lawrence RC, et al; National Arthritis DataWorkgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58(1):15-25.
2. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, CifaldiM. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77-90.
3. Hallert E, HusbergM, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford). 2004;43(11): 1374-1382.
4. Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis. 2011;70(6):1010-1015.
5. Puolakka K, Kautiainen H, Pekurinen M, et al; FIN-RACo Trial Group. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis. 2006;65(7):899-904.
6. Sokka T.Work disability in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5)(suppl 31): S71-S74.
7. BurtonW, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006;56(1):18-27.
8. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii-iv; xi-xiii; 1-229.
9. Bejarano V, Quinn M, Conaghan PG, et al; Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59(10):1467-1474.
10. Breedveld FC,Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versusmethotrexate alone or adalimumab alone in patientswith early, aggressive rheumatoid arthritiswhohad not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
11. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-382.
12. St Clair EW, van der Heijde DM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-3443.
13. Anis A, ZhangW, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford). 2009;48(10):1283-1289.
14. Kimel M, CifaldiM, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35(2):206-215.
15. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(3):716-722.
16. van Vollenhoven RF, CifaldiMA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62(2):226-234.
17. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis. 2010;69(1):126-131.
18. Neovius M, Sundström A, Simard J, et al; ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol. 2011;40(1):8-15.
19. van Vollenhoven RF, Geborek P, Forslind K, et al; Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712-1720.
20. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459-466.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
22. PrevooML, van 't HofMA, Kuper HH, van LeeuwenMA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
23. Efron B. Better bootstrap confidence intervals. J AmStat Assoc. 1987;82(397):171-185.
24. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320(7243):1197-1200.
25. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123-1124.
26. Allaire S,Wolfe F, Niu J, Zhang Y, Zhang B, LaValleyM. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum. 2008;59(8):1082-1089.
27. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, BalaM. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008;59(4):510-514.
28. terWee MM, LemsWF, Usan H, Gulpen A, Boonen A. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012;71(2):161-171.
29. Möttönen T, Hannonen P, Leirisalo-Repo M, et al; FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353(9164):1568-1573.
30. BoersM, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone,methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350(9074):309- 318.
31. Hetland ML, Stengaard-Pedersen K, Junker P, et al; CIMESTRA Study Group. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54(5):1401-1409.
32. Neovius M, Simard JF, Klareskog L, Askling J; ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis. 2011;70(8):1407-1414.